Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience
Journal of Investigative Dermatology · 2023-09 · 143 (9) · 1708-1716.e4
DOI: 10.1016/j.jid.2023.01.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2023-09. Verfasst von Antony Raharja und 11 weiteren Autor:innen. Beteiligte Einrichtung: St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: Drug Monitoring, Psoriasis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Psoriasis Association, NIHR BRC, National Institute for Health and Care Research.
Abstract (Originalsprache)
Serum adalimumab concentration is a biomarker of treatment response but therapeutic drug monitoring (TDM) is yet to be implemented in routine psoriasis care. We incorporated adalimumab TDM in a national specialized psoriasis service and evaluated it using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) implementation science framework. We undertook pre-implementation planning (validating local assays) and implementation interventions targeted to patients (pragmatic sampling at routine reviews), clinicians (introduction of a TDM protocol), and healthcare systems (adalimumab TDM as a key performance indicator). Over 5 months, 170 of 229 (74%) individuals treated with adalimumab received TDM. Clinical improvement after TDM-guided dose escalation occurred in 13 of 15 (87%) nonresponders with serum drug concentrations 8.3 μg/ml; n = 2) or positive antidrug antibody (n = 2) (PASI reduction of 7.8 [interquartile range = 7.5-12.9] after 20.0 weeks). Proactive TDM led to dose reduction in five individuals with clear skin and subtherapeutic or supratherapeutic drug concentrations; four (80%) sustained clear skin after 50 weeks (range = 42-52). Adalimumab TDM based on pragmatic serum sampling is clinically viable and may lead to patient benefit. Context-specific implementation interventions and systematic implementation assessment may bridge the biomarker research-to-practice gap.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
- Reference Chemistry, Synnovis, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom. Electronic address: Satveer.mahil@kcl.ac.uk.
Förderung
- Psoriasis Association
- NIHR BRC
- National Institute for Health and Care Research
Zitieren
APA
Raharja, A., Arkir, Z., Rinaldi, G., Tsakok, T., Dasandi, T., Guard, S., McGuire, A., Pink, A. E., Woolf, R., Barker, J. N., Smith, C. H., & Mahil, S. K. (2023). Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience. Journal of Investigative Dermatology, 143(9), 1708-1716.e4. https://doi.org/10.1016/j.jid.2023.01.033
Vancouver
Raharja A, Arkir Z, Rinaldi G, Tsakok T, Dasandi T, Guard S, et al. Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience. Journal of Investigative Dermatology. 2023;143(9):1708-1716.e4. doi:10.1016/j.jid.2023.01.033
BibTeX
@article{Raharja2023,
author = {Raharja, Antony and Arkir, Zehra and Rinaldi, Giulia and Tsakok, Teresa and Dasandi, Tejus and Guard, Sarah and McGuire, Arlene and Pink, Andrew E and Woolf, Richard and Barker, Jonathan N and Smith, Catherine H and Mahil, Satveer K},
title = {Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience},
journal = {Journal of Investigative Dermatology},
year = {2023},
volume = {143},
number = {9},
pages = {1708--1716.e4},
doi = {10.1016/j.jid.2023.01.033}
}
EUVIMED